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Diarrhea is one of the most significant issues for global
health in children under the age of five. Close to 60% of
mortality in this risk group is caused by pneumonia,
diarrhea or measles, which is usually associated with
malnutrition. In Brazil, this scenario is no different, with
the Northeast semi-arid region having alarming rates of
child mortality, almost twice that of the current national
mortality rate, with some cities being three times higher,
placing child mortality rates in the Northeast of Brazil
among those of the most problematic in the world. The
oral rehydration solution, introduced by the World
Health Organization (WHO), is seen as one of the
major medical advances in the past 50 years, and is
believed to save the lives of 1 to 2 million children each
year. However, the oral rehydration solution simply
restores body fluid normality, treating the consequences
and not the causes of diarrheas. Other means to effec-
tively address worldwide diarrheic ailments still need to
be devised or improved, focusing more on preventive
rather than curative approaches, to prevent or shorten
the course of disease and to minimize recurrences. A
great example is breast-feeding. A series of studies
documented the reduction of diarrhea episodes in
breast-fed children and, also, noted a faster recovery
time following an infection in these children. The posi-
tive benefit of breast milk is attributed to the antimicro-
bial actions of human milk proteins, such as lysozyme
and lactoferrin that can enhance intestinal and systemic
immunological functions. Unfortunately, breast-feeding
is not always an option, especially for toddlers, which is
usually aggravated by undernourishment and low stan-
dard of living, reinforcing the need for alternative strate-
gies. Consequently, to successfully combat childhood
undernourishment, morbidity and mortality in the
Northeast region of Brazil, the investment in approaches
and models that are more suitable to the local semi-arid
adapted agriculture-base is required.
The goat is an important economic asset to the North-
east region, providing milk, meat and leather, with the
number of goats in the Northeast region representing
more than 90% of the Brazilian herd. Historically, goats
have been used as a model in biotechnological studies
involving the expression of specific proteins in the milk
of lactating animals. In this way, the use of goats expres-
sing recombinant human lysozyme (rhLZ) and lactoferrin
(rhLF) in milk is a proven reality that can be employed
for the reduction of malnutrition, infectious diseases and
diarrhea in children in the Brazilian semi-arid region
with an extraordinary potential for success. Due to the
protective nature of human milk imparted, in part, by the
presence of lysozyme and lactoferrin, the generation of
transgenic lines for the production of these important
antimicrobial compounds in the milk of the local goat
population is a unique approach for delivering the poten-
tial protective benefits of human milk. In addition, the
use of rhLZ and rhLF transgenic animals can be used as
a research tool for studying and elucidating the individual
roles of these antimicrobial proteins in gut development
and their synergistic in vivo effects.
The proposed research was designed with the rational
that the transgenic approach can be used to modify the
milk composition of dairy animals to supply milk-borne
human immunocompounds (rhLZ, rhLF) and nutrients
1University of Fortaleza, UNIFOR, Fortaleza, Brazil
Full list of author information is available at the end of the article
Bertolini et al. BMC Proceedings 2014, 8(Suppl 4):O30
http://www.biomedcentral.com/1753-6561/8/S4/O30
© 2014 Bertolini et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
to children in a continuous manner. Therefore when
consumed, this milk would impart enhanced immune
capabilities that would work to benefit the growth and
health of the young and also help in the management of
diarrheal diseases. Genetically modified animal models
for the mammary gland expression of rhLZ, and more
recently rhLF, have been systematically studied at the
University of California at Davis (UC Davis) over the past
20 years, with the milk used for extensive in vitro and in
vivo studies. Lines of transgenic mice and goats with
genetically altered milk for the expression of rhLZ were
created at UC Davis. More recently, investigators at UC
Davis have also initiated parallel and similar studies using
the milk of cows expressing rhLF produced and licensed
by Pharming Inc. Early in this century, a research consor-
tium was created between researchers at UC Davis and
investigators in Brazil at the University of Fortaleza
(UNIFOR) and Federal University of Ceará (UFC), in the
Brazilian northeast region, with the long-term goal of
improving child health by focusing on means to reduce
child mortality and morbidity caused by gastrointestinal
ailments (diarrhea) and malnutrition and also aiming to
promote the development of the Northeast semi-arid
region of Brazil. In 2012, a transgenic goat line producing
rhLZ was produced in Brazil at UNIFOR, with animals
and milk being under investigation focusing on similar
validating in vitro and in vivo studies as performed at UC
Davis, translating results and adapting the studies to the
conditions of the Brazilian northeast region.
The concept of producing a milk with enhanced anti-
microbial properties was first tested in mouse models in
the early 1990s where milk from transgenic mice expres-
sing rhLZ was bacteriostatic against cold-spoilage organ-
isms and a mastitis-causing strain of Staphylococcus
aureus, with results in mice suggesting that rhLZ into
the milk was effective in inhibiting bacterial growth. The
Artemis line of rhLZ transgenic goats was then estab-
lished in 1999 at UC Davis and since then, extensive
and multiple risk assessment studies carried out on the
transgenic line have shown no negative impact of the
presence or expression of the lysozyme transgene on
animal well-being, health, growth, reproduction and
milk production and composition. Furthermore, using
microbial and metabolite profiling techniques to investi-
gate any effects on the physiology of the host (lactating
goats) at the whole animal level, no unintended effects
of transgene expression were found. Milk from rhLZ
transgenic goats possesses enhanced antimicrobial activ-
ity over milk from non-transgenic control goats as it sig-
nificantly slowed the growth of pathogenic bacteria in
vitro. Milk from rhLZ transgenic goats also has a longer
shelf-life with fewer bacteria growing in milk of trans-
genic animals and milk survived at room temperature
for longer periods than control milk before bacterial
growth occurred. Milk from transgenic animals also had a
lower somatic cell count, a measure commonly used to
monitor the state of infection of the mammary gland from
lactation to lactation, thereby indicating modulation by
rhLZ resulting in a healthier udder. Upon consumption by
both ruminant and non-ruminant animal models, pasteur-
ized milk from rhLZ transgenic goats was capable of mod-
ulating intestinal bacteria. Weaning pigs serving as a
human-relevant animal model receiving milk from rhLZ
transgenic animals for 16 days had significantly lower
numbers of coliforms and E. coli in their intestine than did
pigs fed milk from non-transgenic control animals. Com-
pared to control milk-fed pigs, the microbiota of rhLZ-fed
pigs more closely resembled that of human infants being
breast-fed with the enrichment of Bifidobacteriacea and
Lactobacillacea, both biomarkers of increased gut and
host health. These beneficial changes were accompanied
by the reduction of clostridia and Streptococcaceae, which
are components of the fecal microbiota of infants fed for-
mula that lacks lysozyme as well as decreased levels of dis-
ease-related bacteria such as Mycobacteriaceae and
Campylobacterales. This study demonstrated that con-
sumption of lysozyme-rich milk resulted in beneficial
microbe enrichment and detrimental microbe reduction in
the gut microbiome community. Altogether, these data
indicate that rhLZ expressed in the milk of dairy animals
can indeed be biologically active in the intestine and mod-
ulate gut microbiota, much like human milk. Bacterial
challenge work was also conducted in the pig as a human-
relevant medical model. To determine if lysozyme-rich
milk could influence the clinical state of the animal, rhLZ
or control milk was fed to six-week old pigs that had
active diarrhea as induced by administration of a porcine-
specific enterotoxigenic E. coli (ETEC). Pasteurized milk
from rhLZ transgenic or control goats was then given for
48 h. Fecal scores and clinical status were recorded
throughout the trial. Pigs receiving milk from rhLZ trans-
genic animals had significantly improved fecal scores (less
diarrhea) and by the end of the trial suffered from less
dehydration and cleared the infection faster than pigs
receiving control milk. These results demonstrate that
rhLZ alone in milk is enough to have a clinical effect on
the symptoms of diarrhea in the pig model. Finally, two
animal models for malnourishment were recently used to
evaluate the effect of dietary supplementation with rhLZ
goat milk or rhLF cow milk. Using a rat malnourished
model, the daily supplementation with rhLZ goat or con-
trol milk for a period of two weeks resulted in the reestab-
lishment of the body weight and gut morphology in
malnourished rats receiving the transgenic milk to values
similar to full-fed control animals, demonstrating a posi-
tive effect in the physiological recovery from malnourish-
ment. Using a pig model for malnourishment, the
supplementation of the diet with control or rhLF milk
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significantly improved intestinal morphology and perme-
ability, promoting gut recovery and demonstrating that
the administration of both control and rhLF milk was ben-
eficial in the recovery of the gastrointestinal tract. Our
intention is that such milk from transgenic animals can
protect and benefit malnourished children around the
world.
In summary, the data obtained thus far has indicated
no detrimental effects of the transgenic rhLZ goat or
rhLF cattle lines on milk properties and processing, and
on general well-being and animal health. In addition,
milk from lysozyme transgenic goats and lactoferrin
transgenic cows have shown positive impacts on gut
microbiota and morphology, significantly assisting in
mitigating intestinal damage caused by malnutrition,
and helped to resolve E. coli-induced diarrhea and clini-
cal signs more quickly than control milk. This work has
progressed from testing the use of transgenics to modify
the properties of milk in a mouse model to the testing
of the efficacy of the rhLZ and rhLF milk to act at the
level of the intestine in the pig and rat models of
human health. Work is now focusing on the mechanism
of action of rhLZ and rhLF in milk, also moving to the
rat model for additional pharmacological and toxicity
testing as one of the last steps before human clinical
trials. The ongoing studies proposed by the research
consortium represents an important step towards the
ultimate goal of using genetic engineering to improve
the health and quality of animal-based food products
designed for human consumption. The use of milk with
rhLZ and rhLF represents a viable approach to reduce
morbidity and mortality due to diarrhea and malnutri-
tion, thereby resulting in the potential to promote the
development and improvement in the quality of life in
the semi-arid region. The availability of livestock milk
with human milk properties appears to be a potential
food source to enhance and prolong the protective ben-
efits of human milk by promoting disease reduction and
growth enhancement. In fact, the mammary gland trans-
gene expression systems for the production of functional
proteins in the milk of animals have already been pro-
ven as a viable technological alternative to aid in the
resolution of problems of the modern world as a means
of human pharmaceutical production. It is expected and
anticipated that such research efforts will lead to milk
that serves as food to nourish and to protect infants and
children against diarrhea illnesses in unfavorable regions
of the world, also providing an enhanced oral rehydra-
tion solution for diarrheal infections that each year,
according to the WHO, are responsible for the death of
close to a million children worldwide.
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